- Home
- SPRO vs PNI Comparison
SPRO vs PNI Comparison
Compare SPRO & PNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- PNI
- Stock Information
- Founded
- SPRO 2013
- PNI 2002
- Country
- SPRO United States
- PNI United States
- Employees
- SPRO N/A
- PNI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- PNI Trusts Except Educational Religious and Charitable
- Sector
- SPRO Health Care
- PNI Finance
- Exchange
- SPRO Nasdaq
- PNI Nasdaq
- Market Cap
- SPRO 74.0M
- PNI 84.2M
- IPO Year
- SPRO 2017
- PNI N/A
- Fundamental
- Price
- SPRO $1.31
- PNI $7.86
- Analyst Decision
- SPRO Strong Buy
- PNI
- Analyst Count
- SPRO 3
- PNI 0
- Target Price
- SPRO $7.00
- PNI N/A
- AVG Volume (30 Days)
- SPRO 124.6K
- PNI 26.4K
- Earning Date
- SPRO 08-05-2024
- PNI 01-01-0001
- Dividend Yield
- SPRO N/A
- PNI 4.76%
- EPS Growth
- SPRO N/A
- PNI N/A
- EPS
- SPRO 0.33
- PNI N/A
- Revenue
- SPRO $118,459,000.00
- PNI N/A
- Revenue This Year
- SPRO N/A
- PNI N/A
- Revenue Next Year
- SPRO N/A
- PNI N/A
- P/E Ratio
- SPRO $4.12
- PNI N/A
- Revenue Growth
- SPRO 118.43
- PNI N/A
- 52 Week Low
- SPRO $0.99
- PNI $6.03
- 52 Week High
- SPRO $1.89
- PNI $7.89
- Technical
- Relative Strength Index (RSI)
- SPRO 51.95
- PNI 80.60
- Support Level
- SPRO $1.32
- PNI $7.55
- Resistance Level
- SPRO $1.37
- PNI $7.62
- Average True Range (ATR)
- SPRO 0.05
- PNI 0.05
- MACD
- SPRO 0.00
- PNI 0.02
- Stochastic Oscillator
- SPRO 41.18
- PNI 88.24
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.